LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will ...
Chinese hamster ovary (CHO) cell lines are one of the most-used cell-based protein expression systems for therapeutics, thanks to their ability to support post-translational modifications such as ...
Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...
Viral membrane proteins are the proteins of choice in vaccines but are difficult to produce quickly and reliably for use in vaccines, limiting rapid response during emerging outbreaks. Researchers ...
Opportunities lie in the expanding demand for protein therapeutics driven by chronic disease prevalence, advancements in cell-free systems, and personalized medicine. Growth is supported by companies ...
LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results